Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.
作者信息
Winters Mark A, Merigan Thomas C
机构信息
Division of Infectious Diseases and Geographic Medicine, Stanford University, 300 Pasteur Drive, Room S-146, Stanford, California 94305-5107, USA.
出版信息
Antimicrob Agents Chemother. 2005 Jul;49(7):2575-82. doi: 10.1128/AAC.49.7.2575-2582.2005.
Abstract
摘要
相似文献
1
Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.
Antimicrob Agents Chemother. 2005 Jul;49(7):2575-82. doi: 10.1128/AAC.49.7.2575-2582.2005.
2
Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
J Infect Dis. 1999 Aug;180(2):568-71. doi: 10.1086/314909.
3
Antiretroviral Resistance Mutations (revised April 2001).
HIV Clin Trials. 2001 Jul-Aug;2(4):346-55. doi: 10.1310/8FXB-B0EK-D525-BVU3.
4
Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples.
J Infect Dis. 2000 Feb;181(2):740-5. doi: 10.1086/315249.
5
Current insights into reverse transcriptase inhibitor-associated resistance.
Antivir Ther. 2001;6 Suppl 2:11-9.
6
HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations.
Antivir Ther. 2010;15(4):641-50. doi: 10.3851/IMP1571.
7
A fossil record of zidovudine resistance in transmitted isolates of HIV-1.
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13485-7. doi: 10.1073/pnas.251559398.
8
Prevalence of drug resistance mutations in Spain among both naive and pretreated patients.
Antivir Ther. 1999;4 Suppl 3:57-63.
9
Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo.
AIDS Res Hum Retroviruses. 2000 Sep 20;16(14):1385-94. doi: 10.1089/08892220050140937.
10
Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France.
J Antimicrob Chemother. 2010 Dec;65(12):2620-7. doi: 10.1093/jac/dkq380. Epub 2010 Oct 21.
引用本文的文献
1
HIV Protease Hinge Region Insertions at Codon 38 Affect Enzyme Kinetics, Conformational Stability and Dynamics.
Protein J. 2023 Oct;42(5):490-501. doi: 10.1007/s10930-023-10132-6. Epub 2023 Jul 8.
2
Management of Antiretroviral Therapy with Boosted Protease Inhibitors-Darunavir/Ritonavir or Darunavir/Cobicistat.
Biomedicines. 2021 Mar 18;9(3):313. doi: 10.3390/biomedicines9030313.
3
Insertion as a Resistance Mechanism Against Integrase Inhibitors in Several Retroviruses.
Clin Infect Dis. 2019 Sep 27;69(8):1460-1461. doi: 10.1093/cid/ciz136.
4
GS-8374, a prototype phosphonate-containing inhibitor of HIV-1 protease, effectively inhibits protease mutants with amino acid insertions.
J Virol. 2014 Mar;88(6):3586-90. doi: 10.1128/JVI.02688-13. Epub 2013 Dec 26.
5
In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.
Antimicrob Agents Chemother. 2013 Nov;57(11):5500-8. doi: 10.1128/AAC.01195-13. Epub 2013 Aug 26.
6
HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements.
Biochemistry. 2012 Apr 3;51(13):2819-28. doi: 10.1021/bi2018317. Epub 2012 Mar 20.
7
Current and Novel Inhibitors of HIV Protease.
Viruses. 2009 Dec;1(3):1209-39. doi: 10.3390/v1031209. Epub 2009 Dec 11.
8
The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.
Viruses. 2010 Jan 28;2(2):372-394. doi: 10.3390/v2020372.
9
The remarkable frequency of human immunodeficiency virus type 1 genetic recombination.
Microbiol Mol Biol Rev. 2009 Sep;73(3):451-80, Table of Contents. doi: 10.1128/MMBR.00012-09.
10
Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir.
J Virol. 2009 Sep;83(17):8810-8. doi: 10.1128/JVI.00451-09. Epub 2009 Jun 17.
本文引用的文献
1
New two-amino acid insertion near codon 70 of the HIV type 1 protease gene.
AIDS Res Hum Retroviruses. 2005 Apr;21(4):311-3. doi: 10.1089/aid.2005.21.311.
2
3
Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.
J Virol. 2005 Mar;79(6):3536-43. doi: 10.1128/JVI.79.6.3536-3543.2005.
4
Gln145Met/Leu changes in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nucleoside and nonnucleoside analogs and impair virus replication.
Antimicrob Agents Chemother. 2004 Dec;48(12):4611-7. doi: 10.1128/AAC.48.12.4611-4617.2004.
5
Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors.
J Virol. 2004 Nov;78(21):12030-40. doi: 10.1128/JVI.78.21.12030-12040.2004.
6
Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
J Virol. 2004 Sep;78(18):9987-97. doi: 10.1128/JVI.78.18.9987-9997.2004.
7
A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase.
Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11233-8. doi: 10.1073/pnas.0402357101. Epub 2004 Jul 26.
8
Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215.
Virology. 2004 Aug 15;326(1):103-12. doi: 10.1016/j.virol.2004.06.006.
9
Resistance to enfuvirtide, the first HIV fusion inhibitor.
J Antimicrob Chemother. 2004 Aug;54(2):333-40. doi: 10.1093/jac/dkh330. Epub 2004 Jul 1.
10
Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs).
Int J Biochem Cell Biol. 2004 Sep;36(9):1687-705. doi: 10.1016/j.biocel.2004.02.028.
Zotero 插件